Oh Dong Kyu, Kim You-Sun, Oh Yeon-Mok
Department of Pulmonary and Critical Care Medicine, Asan Medical Center, Seoul, Korea.
Asan Institute for Life Sciences, Seoul, Korea.; University of Ulsan College of Medicine, Seoul, Korea.
Tuberc Respir Dis (Seoul). 2017 Jan;80(1):1-10. doi: 10.4046/trd.2017.80.1.1. Epub 2016 Dec 30.
Chronic obstructive pulmonary disease (COPD) is a critical condition with high morbidity and mortality. Although several medications are available, there are no definite treatments. However, recent advances in the understanding of stem and progenitor cells in the lung, and molecular changes during re-alveolization after pneumonectomy, have made it possible to envisage the regeneration of damaged lungs. With this background, numerous studies of stem cells and various stimulatory molecules have been undertaken, to try and regenerate destroyed lungs in animal models of COPD. Both the cell and drug therapies show promising results. However, in contrast to the successes in laboratories, no clinical trials have exhibited satisfactory efficacy, although they were generally safe and tolerable. In this article, we review the previous experimental and clinical trials, and summarize the recent advances in lung regeneration therapy for COPD. Furthermore, we discuss the current limitations and future perspectives of this emerging field.
慢性阻塞性肺疾病(COPD)是一种发病率和死亡率都很高的严重疾病。尽管有几种药物可用,但尚无确切的治疗方法。然而,近年来在肺干细胞和祖细胞的认识以及肺切除术后再肺泡化过程中的分子变化方面取得的进展,使得设想受损肺的再生成为可能。在此背景下,已经开展了许多关于干细胞和各种刺激分子的研究,试图在COPD动物模型中再生受损的肺。细胞疗法和药物疗法都显示出了有前景的结果。然而,与实验室中的成功形成对比的是,尽管临床试验总体上安全且可耐受,但尚无试验展现出令人满意的疗效。在本文中,我们回顾了以往的实验和临床试验,并总结了COPD肺再生治疗的最新进展。此外,我们还讨论了这一新兴领域目前的局限性和未来前景。